MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma
– Zandelisib Demonstrated 70.3% Objective Response Rate; 35.2% Achieved Complete Response – – 9.9% of…